Compare Novavax Inc (NVAX) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Novavax Inc trades at $7.96 (market cap $1.30B), while Invesco S&P 500 Low Volatility ETF trades at $75.6. The key difference: Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | SPLV | |
|---|---|---|
Market Cap | $1.30B | — |
Sector | Health | — |
52-Week High | $11.19 | $77.97 |
52-Week Low | $6.22 | $70.30 |
Enterprise Value | $879.40M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
SPLV trades at $76.21, down 0.07% with neutral technical signals. The ETF focuses on low-volatility S&P 500 stocks, offering stability amid market uncertainty. Recent news highlights its role in diversification as investors seek shelter from tech sell-offs and geopolitical tensions. Moving averages show a bullish trend, while oscillators indicate neutrality, with RSI at 55.45 suggesting balanced momentum.
Outlook: SPLV provides defensive exposure with historical resilience, but reliance on low-volatility factors may lag in bullish markets. Risks include concentrated sector bets and interest rate sensitivity. Analyst sentiment is mixed, reflecting its niche role in risk-averse portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
